Objective:

to describe the evolution and safety of the use of colchicine in outpatients with a diagnosis of mild-moderate COVID-19 in the Integrated Care Management of Albacete.

Methods:

retrospective observational study. Of the 389 participants included in the first recruitment, 315 subjects with valid data were selected. The main variable of the study has been death or hospital admission in patients diagnosed with COVID-19 and treatment with colchicine. Sociodemographic, clinical and treatment variables and concomitant comorbidities were recorded.

Results:

6 (1.90%) patients died and 49 (15.5%) required hospital admission. 58.4% of the patients were prescribed an antibiotic, azithromycin being the most used and responsible for 32.7% of the interactions detected. 34.5% and 43% of the patients received LMWH and corticosteroids, respectively. In 42.3% of the patients, the value of creatinine clearance was not taken into account when dosing colchicine. High age shows a statistically significant relationship with the severity of the symptoms (68.5 vs 58.9) and with the variable relapse (admission + emergency room) (63.25 vs 58.54).

Conclusions:

in our sample, the use of colchicine in outpatients has not modified the course of the disease in patients diagnosed with COVID-19.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )